Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,901–9,000 of 15,747
Promising Immunotherapies against COVID‐19
Guo, H., Zhou, L., Ma, Z., Tian, Z., & Zhou, F. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100044 · Cited by 6
Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination
Dupon, V., Arnaert, S., Haute, E. V., Vulsteke, F., Diet, G., & Schoenmakere, G. D. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.2015101 · Cited by 7
Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env–ferritin nanoparticle designs
Mu, Z., Whitley, J., Martik, D., Sutherland, L. L., Newman, A., Barr, M., Parks, R., Wiehe, K. J., Cain, D. W., Hodges, K. Z., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00137-24 · Cited by 7
“Nucleoside-modified mRNA design for COVID-19 vaccines has been remarkably successful (13, 14) and required a double-proline stabilization mutation in the spike protein (S-2P) for enhanced protein stability and expression (15).”
Clinical outcomes of COVID‐19 treated with remdesivir across the continuum of care
Rivera, C. G., Chesdachai, S., Draper, E. W., Arndt, R. F., Mara, K. C., Suarez, M. L. G., & Razonable, R. R. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13136 · Cited by 5
“Our study examined all hospitalized patients with COVID-19 treated with remdesivir from November 2020 to November 2021, a period that encompasses the pre-vaccination period to the sequential rollout of vaccines to eligible patients.(11,12) Among our cohort of >3000 patients, the mortality rate was 8.”
BackgroundRoper, K. J., Thomas, J., Albalawi, W. O., Maddocks, E., Dobson, S. L., Alshehri, A. A., Barone, F. G., Baltazar, M., Semple, M. G., Ho, A. Y. W., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41928-2 · Cited by 6
Li, J., Li, Z., Zhu, Y., Zhou, L., & Zhu, F. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0025 · Cited by 7
“Similar vaccine efficacy was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions [25].”
BackgroundPhuensan, P., Sirimongkolkasem, J., Tantawichien, T., Phannajit, J., Kerr, S. J., Hansasuta, P., Chantharit, P., Wongsa, A., Fuengfoo, P., Chittinandana, A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23246 · Cited by 6
“By December 2021, ten vaccines including NVX-CoV2373 (Nuvaxovid [1], COVOVAX [2]), mRNA-1273 [3], BNT162b2 [4], 26 CE.”
Nguyễn, V. H., Boileau, C., Bogdanov, A., et al. (2023) · medRxiv · doi:10.1101/2023.02.10.23285603 · Cited by 6
Watanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Fukuzawa, K., & Takagi, T. (2021) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20210104 · Cited by 6
Chen, G., Han, Q., Li, W., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321170121 · Cited by 6
Arias-Cabrales, C., Folgueiras, M., Faura, A., Eguía, J., Padilla, E., Hurtado, S., Ribera, L. B., Echeverría-Esnal, D., Pérez‐Sáez, M. J., Redondo‐Pachón, D., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004433 · Cited by 6
Jumping from Fragment to Drug via Smart Scaffolds
Farahani, M. D., França, T. C. C., Alapour, S., Shahout, F., Boulon, R., Iddir, M., Maddalena, M., Ayotte, Y., & LaPlante, S. R. (2022) · ChemMedChem · doi:10.1002/cmdc.202200092 · Cited by 5
Rizzo, P. A., Bellavia, S., Scala, I., Colò, F., Broccolini, A., Antonica, R., Vitali, F., Angeloni, B. M., Brunetti, V., Iorio, R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236878 · Cited by 6
Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar
Chemaitelly, H. S., Akhtar, N., Jerdi, S. A., Kamran, S., Joseph, S., Morgan, D., Uy, R. S., Abid, F. B., Al‐Khal, A., Bertollini, R., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107095 · Cited by 10
Nonepisodic Angioedema with Eosinophilia Following Receipt of the BNT162b2 mRNA COVID-19 Vaccine
幸田, 太., Natsumoto, B., Shoda, H., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1788-23 · Cited by 6
“Although acute adverse reactions to vaccines, such as a fever and pain, are common and well described, vaccines have been shown to be safe in large-scale trials (1, 2).”
BackgroundCOVID-19 Vaccination: Sociopolitical and Economic Impact in the United States
Jeon, S., Lee, Y.-F. L., & Koumi, K. (2022) · Epidemiologia · doi:10.3390/epidemiologia3040038 · Cited by 7
“[17] reported that a two-dose COVID-19 vaccine by BNT162b2 mRNA reached 95% protection in persons 16 years and older while severe side effects (e.”
BackgroundProgression to Critical Illness and Death in Patients With Breakthrough Hospitalizations
Suleyman, G., Fadel, R. A., Alsaadi, A., Ng-Sueng, L. F., Ghandour, A., Alkhatib, A., Singh, T., Parsons, A. J., Miller, J. B., Ramesh, M. S., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac213 · Cited by 6
“Randomized clinical trials have demonstrated COVID-19 vaccines to be highly effective in preventing symptomatic infections [2, 3], and observational studies have shown that COVID-19 vaccines are highly effective at preventing severe symptomatic disease, hospitalization, and death [4–7].”
BackgroundMok, C. K. P., Tang, Y. S., Tan, C. W., Chong, K. C., Chen, C., Sun, Y., Yiu, K. K. L., Ling, K. C., Chan, K. P., & Hui, D. S. C. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106374 · Cited by 7
Yu, J., Azzam, E. I., Jadhav, A. B., & Wang, Y. (2021) · Cells · doi:10.3390/cells10092212 · Cited by 7
“This stimulated further phase 2 and 3 clinical trials with the BNT162b2 vaccine, with the two-dose regimen showing high efficacy irrespective of age, sex, ethnicity, body-mass index, and pre-existing comorbidities [159,160].”
BackgroundRoberts, M. B., Ferguson, C. C., McCartney, E. M., Selvanderan, K. D., Badiei, A., Paradiso, L., Wallace, C., Torpy, H., Zhang, F., Sim, B., et al. (2022) · Internal Medicine Journal · doi:10.1111/imj.15731 · Cited by 7
“COVID-19 vaccines have been developed and approved with remarkable effectiveness against infection, hospitalisation, severe disease and death (1-3).”
BackgroundBerkane, S., Harizi, I., Tayebi, A., Silverman, M., & Stranges, S. (2022) · International Journal of Public Health · doi:10.3389/ijph.2021.1604312 · Cited by 7
Hong, L., Nian, X., Wu, J., Liu, D., Feng, L. Z., Lu, J., Peng, Y., Zhou, Z., Deng, T., Liu, J., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00496-x · Cited by 6
Germain, R. S., Bossard, E. L., Corey, L., & Sholukh, A. M. (2022) · iScience · doi:10.1016/j.isci.2023.107527 · Cited by 6
“Similarly to the majority of existing vaccines,(4) protection generated by SARS-CoV-2 vaccines was linked to neutralizing antibodies.(3,5,6) However, neutralization failed to solely explain efficacy of vaccine-induced antibody responses in SARS-CoV-2.”
(2022) · doi:10.1101/2022.04.29.22274454 · Cited by 30
Vestibular Neuritis Following COVID-19 Vaccination: A Retrospective Study
Kamogashira, T., Funayama, H., Asakura, S., & Ishimoto, S. (2022) · Cureus · doi:10.7759/cureus.24277 · Cited by 7
“Several types of vaccines have been developed to date against COVID-19 with the aim of controlling the pandemic and its socioeconomic impact [4], including Tozinameran (BioNTech-Pfizer, Comirnaty, BNT162b2) [5], Elasomeran (Moderna, Spikevax, mRNA-1273) [6], ChAdOx1 nCoV19 (AstraZeneca-Oxford University, Vaxzevria, AZ…”
BackgroundZhang, H., Ma, J., Pan, F., Liu, Y., Zhang, M., Li, Y., Zhang, C., Huang, H., Zhang, W., Xiu, D., et al. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01217a · Cited by 8
Christensen, D., Polacek, C., Sheward, D. J., Hanke, L., McInerney, G. M., Murrell, B., Hartmann, K. T., Jensen, H. E., Zimmermann, J., Jungersen, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.941281 · Cited by 6
Advances in Surrogate Neutralization Tests for High-Throughput Screening and the Point-of-Care
Streif, S., & Baeumner, A. J. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00666 · Cited by 8
Case of reactive sacroiliitis possibly induced by an mRNA coronavirus disease vaccine
Roux, N., Poussing, S., & Maurier, F. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-249063 · Cited by 8
Bhochhibhoya, A., Branscum, P., Thapaliya, R., Ghimire, P. S., & Wharton, H. (2021) · American Journal of Health Education · doi:10.1080/19325037.2021.1955231 · Cited by 9
“As of May 25, 2021, we have more data to support the effectiveness of the COVID-19 vaccine in curbing COVID-19-related mortality and morbidity; thus, the importance of getting vaccinated is growing.(49,50) This study further helps by identifying the specific population and their explicit beliefs in terms of hesitancy…”
MethodPopulation impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape
Bushman, M., Kahn, R., Taylor, B., Lipsitch, M., & Hanage, W. (2021) · medRxiv · doi:10.1101/2021.08.26.21262579 · Cited by 96
“Most authorized vaccines demonstrate at least 70% efficacy against symptomatic COVID19, and a few approach or exceed 90% efficacy [22-27].”
BackgroundTani, N., Ikematsu, H., Goto, T., Gondo, K., Yanagihara, Y., Kurata, Y., Oishi, R., Minami, J., Onozawa, K., Nagano, S., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100224 · Cited by 6
Omicron and vaccines: An analysis on the decline in COVID-19 mortalityPreprint
Larrauri, B. J., Malbrán, A., & Larrauri, J. A. (2022) · medRxiv · doi:10.1101/2022.05.20.22275396 · Cited by 8
Newcomb, K., Bilal, S., & Michael, E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277521 · Cited by 7
Palalay, H., Vyas, R., & Tafuto, B. A. (2023) · World Journal of Meta-Analysis · doi:10.13105/wjma.v11.i5.167 · Cited by 10
Elmahdi, R., Ward, D., Ernst, M. T., Poulsen, G., Hallas, J., Pottegård, A., & Jess, T. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-077408 · Cited by 7
“1 Premarketing trials excluded individuals considered at risk of immunocompromise, including those receiving immunosuppressive therapies 2 3 ; therefore, there remains a paucity of data on the real-world effectiveness of SARS- CoV-2 vaccines in patients treated with immunosuppressive drugs.”
BackgroundBernhauerová, V. (2022) · Nature Ecology & Evolution · doi:10.1038/s41559-022-01748-5 · Cited by 6
Taha, A. E., Alduraywish, A. A., Almaeen, A. H., El‐Metwally, T. H., Alayyaf, M., Mallick, A., & Abouelkheir, M. M. (2022) · Vaccines · doi:10.3390/vaccines11010026 · Cited by 7
Meggiolaro, A., Schepisi, M. S., Nikolaidis, G., et al. (2021) · medRxiv · doi:10.1101/2021.08.25.21262529 · Cited by 7
“1) Only SARS-CoV-2 cases 143 occurred at least one week after the second dose were attributed to the lack of vaccine 144 protection.[6] Moreover, cases occurred within these seven days were still attributed to the first 145 dose effectiveness (Fig.”
InfluentialAdaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
Bader, G., Itan, M., Edry‐Botzer, L., Cohen, H., Haskin, O., Mozer‐Glassberg, Y., Harel, L., Munitz, A., Marcus, N., & Gerlic, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131965 · Cited by 5
“To combat the destructive effects of COVID-19, several vaccines have been rapidly developed, including the Pfizer-Biontech BNT162b2 mRNA vaccine (10, 11).”
BackgroundZadok, O. I. B., Shaul, A. A., Ben‐Avraham, B., Yaari, V., Zvi, H. B., Eliakim‐Raz, N., Yahav, D., Abed, G., Abuhazira, M., Barac, Y. D., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13798 · Cited by 5
Mori, Y., Miyatake, N., Suzuki, H., Okada, S., & Tanimoto, K. (2021) · Vaccines · doi:10.3390/vaccines9111282 · Cited by 6
Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2?
Riccò, M., Nard, F. D., & Peruzzi, S. (2021) · Infectious Diseases Now · doi:10.1016/j.idnow.2021.03.001 · Cited by 6
The association between excess weight and COVID‐19 outcomes: An umbrella review
Matu, J., Griffiths, A., Shannon, O. M., Jones, A., Day, R. E., Radley, D., Feeley, A. B., Mabbs, L., Blackshaw, J., Sattar, N. A., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13803 · Cited by 7
The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report
Chen, S.-Y., Lin, C., Chi, H., Weng, S., Li, S.-T., Tai, Y., Huang, Y.-N., Huang, H. Y., Lin, C., & Chiu, N. (2023) · Life · doi:10.3390/life13102094 · Cited by 7
Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval?
Mörl, F., Gunther, M. M., & Rockenfeller, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.879120 · Cited by 6
“(6), Supplementary Table 3]: In category “serious” instead of “severe”, counts are 126 (vac) and 111 (com), thus, hbr = 3.”
BackgroundTesting Different COVID-19 Vaccination Strategies Using an Agent-Based Modeling Approach
Trad, F. S., & Falou, S. E. (2022) · SN Computer Science · doi:10.1007/s42979-022-01199-6 · Cited by 6
“Currently, our study has two main limitations: • The lack of medical information about different kinds of vaccines (transmission risk, effectiveness, etc.), and this is why we only simulated the Pfizer vaccine since we were able to get most of the necessary related data.”
BackgroundInfluentialNucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention
Tarrés-Freixas, F., Clotet, B., Carrillo, J., & Blanco, J. (2024) · Vaccines · doi:10.3390/vaccines12030298 · Cited by 6
“…human use, either as deoxyribnonucleic acid Vaccines 2024 , 12 , 298 2 of 23 (DNA) vaccines [5], or messenger ribonucleic acid (mRNA) vaccines [6,7]. mRNA vaccines proved to be especially efficacious and competitive, and they are considered as one of the vaccine platforms that might achieve the…”
BackgroundFurlong, E., Kotecha, R. S., Conyers, R. K., O'Brien, T. A., Hansford, J. R., Super, L., Downie, P., Eisenstat, D. D., Haeusler, G. M., McMullan, B. J., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51444 · Cited by 5
Hemiacetal-linked pH-sensitive PEG-lipids for non-viral gene delivery
Coelho, F., Salonen, L. M., & Silva, B. F. B. (2022) · New Journal of Chemistry · doi:10.1039/d2nj02217f · Cited by 8
Rodríguez-Mora, S., Corona, M., Torres, M., Casado‐Fernández, G., García‐Pérez, J., Ramos-Martín, F., Vigón, L., Manzanares, M., Mateos, E., Martín‐Moro, F., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102803 · Cited by 8
Ahmed, M. I. M., Einhauser, S., Peiter, C., Senninger, A., Baranov, O., Eser, T. M., Huth, M., Olbrich, L., Castelletti, N., Rubio‐Acero, R., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110138 · Cited by 6
He, W.-T., Musharrafieh, R., Song, G., Dueker, K., Tse, L.-P. V., Martinez, D. R., Schäfer, A., Callaghan, S., Yong, P., Beutler, N., et al. (2021) · bioRxiv · doi:10.1101/2021.09.08.459480 · Cited by 3
Sibanda, B., & Haryanto, B. (2024) · Annals of Global Health · doi:10.5334/aogh.4484 · Cited by 12
Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male
Sütçü, M., Gül, D., Atík, F., & Kara, M. (2022) · Malawi Medical Journal · doi:10.4314/mmj.v34i2.13 · Cited by 6
Plasma EV-miRNAs as Potential Biomarkers of COVID-19 Vaccine Immune Response in Cancer Patients
Almeida, B., Dias, T. R., Cruz, P., Sousa‐Pimenta, M., Teixeira, A. L., Pereira, C. E., Costa‐Silva, B., Oliveira, J., Medeiros, R., & Dias, F. (2024) · Vaccines · doi:10.3390/vaccines12080848 · Cited by 6
“Findings from the human trials of the Pfizer/BioNTech mRNA vaccine demonstrated 95% maximal protection within seven or more days after the second vaccine dose, including against several circulating variants of concern [25].”
MethodOrillard, É., Spehner, L., Mansi, L., Bouard, A., Falcoz, A., Lepiller, Q., Renaude, E., Pallandre, J., Vienot, A., Kroemer, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160664 · Cited by 7
Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
He, X., & Zeng, X. X. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s347297 · Cited by 8
Dai, G., Feinberg, A. W., & Wan, L. Q. (2021) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-021-00676-x · Cited by 6
Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey
Mathema, B., Chen, L., Wang, P., Cunningham, M. H., Mediavilla, J. R., Chow, K. F., Luo, Y., Zhao, Y., Composto, K., Zuckerman, J. M., et al. (2022) · mBio · doi:10.1128/mbio.02141-22 · Cited by 6
“We also examined a panel of convalescent-phase plasma samples obtained from 20 SARS-CoV-2 patients (collected 1 month after documented infection) and vaccinee sera obtained from 12 individuals who had received the mRNA-1273 SARS-CoV-2 vaccine (collected on day 43; with two doses) and 10 individuals who had received th…”
MethodLaturski, A. E., Dulay, M. T., Perry, J. L., & DeSimone, J. M. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00028 · Cited by 7
COVID-19 Diagnosis and Risk of Death Among Adults With Cancer in Indiana: Retrospective Cohort Study
Valvi, N. R., Patel, H., Bakoyannis, G., Haggstrom, D. A., Mohanty, S., & Dixon, B. E. (2022) · JMIR Cancer · doi:10.2196/35310 · Cited by 6
Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation
Olmedillas, E., Rajamanickam, R. R., Avalos, R. D., Sosa, F. A., Zandonatti, M. A., Harkins, S. S., Shresta, S., Hastie, K. M., & Saphire, E. O. (2023) · doi:10.1101/2023.12.14.571764 · Cited by 19
Stein, M. L., Park, R. S., Afshari, A. J., et al. (2021) · Pediatric Anesthesia · doi:10.1111/pan.14272 · Cited by 6
Grewe, I., Friedrich, M., Dieck, M.-L., Spohn, M., Ly, M. L., Krähling, V., Mayer, L., Mellinghoff, S. C., Rottstegge, M., Kraemer, R., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1500615 · Cited by 9
A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19
Yeo, J. G., Leong, J. Y., Tay, S. H., Nadua, K. D., Anderson, D. E., Lim, A. J. M., Ng, X. W., Poh, S. L., Guo, D., Yaung, K. N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674279 · Cited by 7
Make It or Break It: Vaccination Intent at the Time of COVID-19
Bughin, J., Cincera, M., Peters, K., Reykowska, D., Żyszkiewicz, M., & Ohme, R. K. (2020) · Vaccine · doi:10.1016/j.vaccine.2023.02.014 · Cited by 9
“Taking the case of the H1N1 pandemic again in 2009, institutions from countries such as Netherlands and Sweden quickly initiated an aggressive vaccination campaign in the early days of the pandemic.”
BackgroundInfluentialVertigo/dizziness following COVID-19 vaccination
Yan, H., & Young, Y. (2022) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2022.103723 · Cited by 9
“Thereafter, several types of vaccines against COVID-19 infection have been released for controlling the pandemic and its socioeconomic impact [2], including Elasomeran (Moderna, Spikevax, mRNA-1273), briefly Moderna vaccine [3]; Tozinameran (Pfizer-BioNTech, Comirnaty, BNT162b2), briefly BNT vaccine [4]; Ad26.”
BackgroundMukherjee, D., & Bhatt, S. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0425 · Cited by 6
Pageaud, S., Pothier, C., Rigotti, C., Eyraud-Loisel, A., Bertoglio, J. P., Bienvenüe, A., Leboisne, N., Ponthus, N., Gauchon, R., Gueyffier, F., et al. (2021) · Vaccines · doi:10.3390/vaccines9121462 · Cited by 5
“Vaccination Effects The expected effects of vaccination were set at their most recently estimated levels of efficacy in preventing severe forms of the disease; that is, 94% [5,6] and 75% [4], depending on the vaccine.”
Agrawal, N., Ates, L. S., Schille, S. A., Chaturvedi, A., Vogt, J., Vukovic, N., Dulberger, C. L., Vogel, A. B., Diekmann, J., Diken, M., et al. (2026) · Nature Immunology · doi:10.1038/s41590-026-02545-z · Cited by 19
“…that mRNA-based platforms would be appropriate for TB vaccine development, as they can induce robust cellular (CD4 + and CD8 + ) and antibody responses 16 . mRNA vaccines developed against COVID-19 may also provide valuable platform learnings that could be applied to TB vaccine development 17–19 .”
InfluentialSelf-citationSARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021
Yi, S., Choe, Y. J., Kim, J., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2803.212210 · Cited by 6
“05% of Pfizer-BioNTech recipients (6) and 0.”
BackgroundFibke, C. D., Joffres, Y., Tyson, J. R., Colijn, C., Janjua, N. Z., Fjell, C. D., Prystajecky, N., Jassem, A. N., & Sbihi, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.915363 · Cited by 8
“Both Moderna mRNA-1273 and Pfizer–BioNTech BNT162b2 vaccines have shown high effectiveness at preventing severe COVID-19 related illness by around 95% (3, 5).”
BackgroundMolecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies
Santamaria-Castro, I., Leiva-Rebollo, R., Marín‐Wong, S., Jiménez-Guardeño, J. M., & Ortega‐Prieto, A. M. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00260-24 · Cited by 7
Answers to common questions about COVID‐19 vaccines in children with cancer
Caniza, M. A., Homsi, M. R., Bate, J. M., Adrizain, R., Ahmed, T., Alexander, S. W., Bhattacharyya, A., Copado-Gutiérrez, J. L., Gutiérrez-Tobar, I. F., Lim, Y. Y., et al. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.29985 · Cited by 7
Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic
Zhu, F., Ma, S., Xu, Y., Zhou, Z., Zhang, P., Peng, W., Yang, H., Tan, C., Chen, J., & Pan, P. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012815 · Cited by 6
Modeling the impact of early vaccination in an influenza pandemic in the United States
Nguyễn, V. H., Crépey, P., Williams, B. A., Welch, V., Pivette, J. M., Jones, C. H., & True, J. M. (2025) · npj Vaccines · doi:10.1038/s41541-025-01081-5 · Cited by 9
Current challenges in different approaches to control COVID-19: a comprehensive review
Giri, S., Sen, S., Singh, R., Paul, P., Sahu, R., Nandi, G., & Dua, T. K. (2022) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-022-00730-2 · Cited by 8
“Storage (°C) References BNT162b2 (Comirnaty) Pfizer-BioNtech USA and Germany mRNA IM (2) 95 − 80 to – 60 Polack et al. (2020) mRNA-1273 (Moderna COVID-19 Vaccine) Moderna USA mRNA IM (2) 94.0 − 25 to − 15 Baden et al. (2021) Ad26.”
InfluentialCOVID-19 Vaccination Perceptions Among Young Adults of Color in the San Francisco Bay Area
Ríos‐Fetchko, F., Carson, M. S., Ramirez, M. G., et al. (2022) · Health Equity · doi:10.1089/heq.2022.0068 · Cited by 6
Recurrence of thrombotic thrombocytopenic purpura after vaccination with mRNA-1273 COVID-19 vaccine
Ntelis, S., & Champ, K. G. (2022) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1073 · Cited by 6
Key steps in our journey to a COVID‐19 vaccine program
Blyth, C. C., Flanagan, K. L., Gibbs, R. A., et al. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.50978 · Cited by 6
Jangra, S., Vrieze, J. D., Choi, A., Rathnasinghe, R., Laghlali, G., Uvyn, A., Herck, S. V., Nuhn, L., Deswarte, K., Zhong, Z., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202015362 · Cited by 6
Pilli, T., Dalmiglio, C., Dalmazio, G., Sagnella, A., Forleo, R., Brilli, L., Maino, F., Ciuoli, C., & Castagna, M. G. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1236 · Cited by 6
Sharma, K., Patel, S., Patel, Z., Patel, K. B., Shah, D. B., Doshi, J. S., Chokshi, P., Sharma, C., Amdani, M. M., Parabtani, A., et al. (2022) · Cureus · doi:10.7759/cureus.26480 · Cited by 7
“According to the estimates, one de novo incidence would occur for every million vaccination recipients, which is consistent with the zero occurrences recorded in the joint Pfizer and Moderna vaccine trials, which included over 70,000 participants [32,33].”
BackgroundResultStellenwert der COVID-19-Impfung im Kontext von Long-COVID
Bauernfeind, S., & Schmidt, B. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01368-y · Cited by 8
Phumisantiphong, U., Chunhakan, S., Manomaipiboon, A., Maneerit, J., Dechanuwong, P., Trakarnvanich, T., Oajaum, W., & Chan-in, W. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100277 · Cited by 6
“Since August 2021, three booster vaccines are available: ChAdOx1 nCoV-19 (Oxford–AstraZeneca; AZ), a viral vector vaccine [8], BNT162b2 (Pfizer-BioNTech; PZ) [9], and mRNA-1273 (Moderna), messenger RNA vaccines [10].”
Twitter communities are associated with changing user’s opinion towards COVID-19 vaccine in Japan
Wu, Q., Sano, Y., Takayasu, H., Havlin, S., & Takayasu, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-95595-6 · Cited by 11
Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
Segundo, D. S., Comins‐Boo, A., Irure‐Ventura, J., Renuncio‐García, M., Roa‐Bautista, A., González-López, E., Merino-Fernández, D., Lamadrid-Perojo, P., Alonso‐Peña, M., Ocejo-Vinyals, J. G., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9080868 · Cited by 6
“The efficacy of vaccinations is measured through incidence of infection, which seems to be very low (<5%) with mRNA COVID-19 vaccines [1,4].”
BackgroundPalacka, P., Polanová, M., Svobodová, A., Zigmond, J., Zanchetta, K., Gombarova, V., Vulganova, M., Slopovský, J., Obertová, J., Drgoňa, Ľ., et al. (2022) · Vaccines · doi:10.3390/vaccines10040558 · Cited by 6
“This supported the selection of BNT162b2 for advancement to a phase II/III trial [7], which showed 95% efficacy in preventing COVID-19 and similar safety to that of other viral vaccines at a median of 2 months.”
MethodAl-Wassiti, H. A., Fabb, S. A., Grimley, S. L., Kochappan, R., Ho, J. K., Wong, C. Y., Tan, C. W., Payne, T. J., Takanashi, A., Lee, C. L., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101380 · Cited by 8
Marfoh, K., Samba, A., Okyere, E., Acheampong, F., Owusu, E., Darko, D. N. A., Zakariah, J., Mensa, H., Aidoo, E., & Mohammed, Y. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-061643 · Cited by 7
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.